KangaBio and Immune Targeting Inc. sign a cooperation agreement
Time：2021-05-31

In May 2021, KangaBio and Immune Targeting Inc. (hereinafter referred to as “ITI”) have reached cooperation on cytokine prodrug products and signed a license agreement. This product is a cytokine prodrug developed by ITI for the treatment of solid tumors with reduced toxicity and side effects. The agreement granted KangaBio the exclusive rights to develop and commercialize this product worldwide.